化驗
~95%
儲存溫度
2-8°C
SMILES 字串
OC(=O)\C=C\C(O)=O.COc1cc(N)c(Cl)cc1C(=O)NC2CCN(CC2)Cc3ccccc3
InChI
1S/C20H24ClN3O2.C4H4O4/c1-26-19-12-18(22)17(21)11-16(19)20(25)23-15-7-9-24(10-8-15)13-14-5-3-2-4-6-14;5-3(6)1-2-4(7)8/h2-6,11-12,15H,7-10,13,22H2,1H3,(H,23,25);1-2H,(H,5,6)(H,7,8)/b;2-1+
InChI 密鑰
BCVIWCRZYPHHMQ-WLHGVMLRSA-N
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
Eyeshields, Gloves, type N95 (US)
[Acute laryngeal dystonia due to clebopride simulating allergic reaction].
Mercè Corominas Sánchez et al.
Medicina clinica, 129(6), 238-239 (2007-08-07)
Domenico Bosco et al.
Clinical neuropharmacology, 32(2), 107-108 (2009-06-11)
Dystonic reactions produce twisting and repetitive movements or abnormal posturing. Severe dystonic reactions have been shown to occur in concert with numerous medications. This report details the case of a patient who developed hemifacial dystonia as acute side reaction from
Partial least-squares regression for the quantitation of pharmaceutical dosages in control analyses.
M Blanco et al.
Journal of pharmaceutical and biomedical analysis, 15(3), 329-338 (1996-12-01)
A spectrophotometric method for the simultaneous determination of the active principle and a flavouring agent in syrups containing additional excipients is proposed. The calibration matrix must include all the variability expected in the samples and this is achieved using laboratory-made
Jaume Campdelacreu et al.
Movement disorders : official journal of the Movement Disorder Society, 19(4), 482-484 (2004-04-13)
We report on a patient who presented with a progressive supranuclear palsy (PSP) syndrome while receiving clebopride (CLB), a prokinetic drug with central antidopaminergic properties. The clinical and neurophysiological signs progressively disappeared after CLB withdrawal. To our knowledge, this is
E M Byrnes et al.
Developmental psychobiology, 29(8), 653-666 (1996-12-01)
D1- and D2-like antagonist-induced catalepsy and dorsal immobility were studied in pups (Day 10) and weanlings (Days 20, 28, or 35) that received intraventricular injection of 6-OHDA (50 micrograms/hemisphere) or its vehicle solution or postnatal Day 3. The ability of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门